 |
|
COMMENTS AND OPINIONS
Men, Androgen Deficiency, and Pharmaceutical Promotion—Reply
Susan A. Hall, PhD;
Andre B. Araujo, PhD;
Thomas G. Travison, PhD;
Gretchen R. Esche, MS;
John B. McKinlay, PhD;
Richard V. Clark, MD, PhD;
Rachel E. Williams, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
Dr Finucane suggests that symptomatic androgen deficiency was arbitrarily defined in the Boston Area Community Health (BACH) study1 and seems to imply that the study was a "disease creation" effort related to pharmaceutical marketing. This study was sponsored by the National Institutes of Health, with additional financial support from GlaxoSmithKline for these analyses, as we disclosed in our article. Our disease definition was not arbitrary but based on published clinical practice guidelines from the Endocrine Society, the medical authority on this topic.2 We used a combination of low total testosterone level + low free testosterone + the presence of symptoms (both specific [eg, low libido, osteoporosis, and erectile dysfunction] and nonspecific symptoms). We recognize that there is significant debate over what threshold constitutes . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Treatment of Symptomatic Androgen Deficiency: Results From the Boston Area Community Health Survey
Susan A. Hall, Andre B. Araujo, Gretchen R. Esche, Rachel E. Williams, Richard V. Clark, Thomas G. Travison, and John B. McKinlay
Arch Intern Med. 2008;168(10):1070-1076.
ABSTRACT
| FULL TEXT
RELATED LETTER
Men, Androgen Deficiency, and Pharmaceutical Promotion
Thomas E. Finucane
Arch Intern Med. 2009;169(1):88.
EXTRACT
| FULL TEXT
|
